3rd Quarter - Report
BROWNSTEIN HYATT FARBER SCHRECK, LLP for AMGEN USA INC.
Client
Income
$50,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to the 340B Drug Discount Program; Medicare Part D; Medicare Part B; S. 1416 - Affordable Prescriptions for Patients Act of 2019; H.R.3 - Lower Drug Costs Now Act of 2019; H.R. 2693 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| NADEAM ELSHAMI | — |
| EMILY FELDER New | Director of the Office of Legislation, CMS; Counsel, House Energy and Commerce Committee; Counsel, Senate Committee on Homeland Security and Government Affairs; Counsel, House Oversight and Government Reform Committee |
| ELIZABETH ANNE MAIER | — |
| ALFRED MOTTUR | — |
| JEROME MURRAY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.